NCT00147212View on ClinicalTrials.gov

ET 743 (Yondelis) in Men With Advanced Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Prostate Cancer
Interventions
DRUG

ET 743

ET-743 administered IV by 24-hr infusion every 3 weeks

Trial Locations (2)

02114

Masachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

PharmaMar
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

PharmaMar

INDUSTRY

lead

Massachusetts General Hospital

OTHER